Proton pump inhibitors (PPIs) are very effective and suitable for certain indications and treatment periods, but there is an increasing trend towards “off-label” prescriptions. To ensure that temporary administration for a specific indication does not become an unreflected permanent medication, North American experts have summarized ten best practice recommendations to help decide whether discontinuation (“deprescribing”) of PPIs could be an option to consider.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- GASTROENTEROLOGIE PRAXIS
Related Topics
You May Also Like
- AI in neurology
Control instead of a flood of data: AI makes big data and wearables usable
- Participation of the patient
Adherence in psychiatry
- Eosinophilic esophagitis
EoE rarely occurs in isolation
- Lung cancer with EGFR mutation
New perspectives in first-line therapy
- Sleep disorder
Sleep medicine in transition: new goals and a reassessment of old hypnotics
- Ginkgo biloba extract in the Alzheimer's mouse model
Effects on disease-associated microglia subpopulations
- "Patients W.A.I.T Indicator"
Access to medicines – how does Switzerland compare across Europe?
- Osteoporosis